Applied multiplex allele specific PCR to detect second-line drug resistance among multidrug-resistant tuberculosis in China
Rapid detection of resistance to the second-line drugs is essential for early initiation of appropriate anti-tubercular treatment regimen among multi-drug tuberculosis (MDR-TB). In this study, we applied a multiplex allele-specific PCR (MAS-PCR) to identify the mutations on codons 90 and 94 of gyrA...
Gespeichert in:
| Veröffentlicht in: | Tuberculosis (Edinburgh, Scotland) Scotland), 2017-12, Vol.107, p.1-4 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4 |
|---|---|
| container_issue | |
| container_start_page | 1 |
| container_title | Tuberculosis (Edinburgh, Scotland) |
| container_volume | 107 |
| creator | Liang, Ya-ping Chen, Yan Xiao, Tong-yang Xia, Qiang Liu, Hai-can Zhao, Xiu-qin Zeng, Chun-yan Zhao, Li-li Wan, Kang-lin |
| description | Rapid detection of resistance to the second-line drugs is essential for early initiation of appropriate anti-tubercular treatment regimen among multi-drug tuberculosis (MDR-TB). In this study, we applied a multiplex allele-specific PCR (MAS-PCR) to identify the mutations on codons 90 and 94 of gyrA and nucleotide 1401 of rrs for detecting ofloxacin (OFX) and kanamycin (KAN) resistance in 139 MDR-TB isolates from China. Using the traditional phenotypic method as the reference, MAS-PCR detected resistance to OFX and KAN with sensitivities of 67.3% and 76.5%, respectively, and specificities of 100.0%. Therefore, MAS-PCR assays can be used for rapid detection of second-line drug resistance among MDR-TB in China, enabling early administration of appropriate treatment regimens to the affected MDR-TB patients. |
| doi_str_mv | 10.1016/j.tube.2017.07.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1954065943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1472979216303006</els_id><sourcerecordid>1954065943</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-311222d5797101fb7396ca03fba87d2906bd5501372ac6c682a346c452eab94c3</originalsourceid><addsrcrecordid>eNp9kEtr3DAUhUVp6KRp_0AXRctuPNHDsmzIJgzpAwYSQgLdCVm6nmqQH5HkkJA_H5mZdBm4IKF7zkHnQ-gbJWtKaHW-X6e5hTUjVK5JHko-oFNaS16wmv79mO-lZEUjG7ZCn2Pck2wiNfmEVqwhgkghTtHL5TR5Bxb3s09u8vCEtffgAccJjOucwTebW5xGbCGBSTiCGQdbeDcAtmHe4QDRxaQHA1j347A7JC2r4m2V8PLRYGY_5gfsBrz55wb9BZ102kf4ejzP0P3Pq7vN72J7_evP5nJbGC6qVHBKGWNWyEbm2l0reVMZTXjX6lraXKVqrRCEcsm0qUxVM83LypSCgW6b0vAz9OOQO4XxYYaYVO-iAe_1AOMcFW1ESSrRlDxL2UFqwhhjgE5NwfU6PCtK1AJd7dXSRS3QFclDSTZ9P-bPbQ_2v-WNchZcHASQWz46CCoaB5mYdSEzVXZ07-W_Aje_lKs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1954065943</pqid></control><display><type>article</type><title>Applied multiplex allele specific PCR to detect second-line drug resistance among multidrug-resistant tuberculosis in China</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Liang, Ya-ping ; Chen, Yan ; Xiao, Tong-yang ; Xia, Qiang ; Liu, Hai-can ; Zhao, Xiu-qin ; Zeng, Chun-yan ; Zhao, Li-li ; Wan, Kang-lin</creator><creatorcontrib>Liang, Ya-ping ; Chen, Yan ; Xiao, Tong-yang ; Xia, Qiang ; Liu, Hai-can ; Zhao, Xiu-qin ; Zeng, Chun-yan ; Zhao, Li-li ; Wan, Kang-lin</creatorcontrib><description>Rapid detection of resistance to the second-line drugs is essential for early initiation of appropriate anti-tubercular treatment regimen among multi-drug tuberculosis (MDR-TB). In this study, we applied a multiplex allele-specific PCR (MAS-PCR) to identify the mutations on codons 90 and 94 of gyrA and nucleotide 1401 of rrs for detecting ofloxacin (OFX) and kanamycin (KAN) resistance in 139 MDR-TB isolates from China. Using the traditional phenotypic method as the reference, MAS-PCR detected resistance to OFX and KAN with sensitivities of 67.3% and 76.5%, respectively, and specificities of 100.0%. Therefore, MAS-PCR assays can be used for rapid detection of second-line drug resistance among MDR-TB in China, enabling early administration of appropriate treatment regimens to the affected MDR-TB patients.</description><identifier>ISSN: 1472-9792</identifier><identifier>EISSN: 1873-281X</identifier><identifier>DOI: 10.1016/j.tube.2017.07.010</identifier><identifier>PMID: 29050755</identifier><language>eng</language><publisher>Scotland: Elsevier Ltd</publisher><subject>Antitubercular Agents - therapeutic use ; Bacteriological Techniques ; China ; DNA Gyrase - genetics ; DNA Mutational Analysis - methods ; Drug Resistance, Multiple, Bacterial - genetics ; Genotype ; Humans ; Kanamycin ; Kanamycin - therapeutic use ; Kanamycin Resistance - genetics ; Microbial Sensitivity Tests ; Multidrug-resistant tuberculosis ; Multiplex allele specific PCR ; Multiplex Polymerase Chain Reaction ; Mutation ; Mycobacterium tuberculosis - drug effects ; Mycobacterium tuberculosis - genetics ; Mycobacterium tuberculosis - pathogenicity ; Ofloxacin ; Ofloxacin - therapeutic use ; Predictive Value of Tests ; Ribosomal Proteins - genetics ; Tuberculosis, Multidrug-Resistant - diagnosis ; Tuberculosis, Multidrug-Resistant - drug therapy ; Tuberculosis, Multidrug-Resistant - microbiology</subject><ispartof>Tuberculosis (Edinburgh, Scotland), 2017-12, Vol.107, p.1-4</ispartof><rights>2017 Elsevier Ltd</rights><rights>Copyright © 2017 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-311222d5797101fb7396ca03fba87d2906bd5501372ac6c682a346c452eab94c3</citedby><cites>FETCH-LOGICAL-c356t-311222d5797101fb7396ca03fba87d2906bd5501372ac6c682a346c452eab94c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.tube.2017.07.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29050755$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liang, Ya-ping</creatorcontrib><creatorcontrib>Chen, Yan</creatorcontrib><creatorcontrib>Xiao, Tong-yang</creatorcontrib><creatorcontrib>Xia, Qiang</creatorcontrib><creatorcontrib>Liu, Hai-can</creatorcontrib><creatorcontrib>Zhao, Xiu-qin</creatorcontrib><creatorcontrib>Zeng, Chun-yan</creatorcontrib><creatorcontrib>Zhao, Li-li</creatorcontrib><creatorcontrib>Wan, Kang-lin</creatorcontrib><title>Applied multiplex allele specific PCR to detect second-line drug resistance among multidrug-resistant tuberculosis in China</title><title>Tuberculosis (Edinburgh, Scotland)</title><addtitle>Tuberculosis (Edinb)</addtitle><description>Rapid detection of resistance to the second-line drugs is essential for early initiation of appropriate anti-tubercular treatment regimen among multi-drug tuberculosis (MDR-TB). In this study, we applied a multiplex allele-specific PCR (MAS-PCR) to identify the mutations on codons 90 and 94 of gyrA and nucleotide 1401 of rrs for detecting ofloxacin (OFX) and kanamycin (KAN) resistance in 139 MDR-TB isolates from China. Using the traditional phenotypic method as the reference, MAS-PCR detected resistance to OFX and KAN with sensitivities of 67.3% and 76.5%, respectively, and specificities of 100.0%. Therefore, MAS-PCR assays can be used for rapid detection of second-line drug resistance among MDR-TB in China, enabling early administration of appropriate treatment regimens to the affected MDR-TB patients.</description><subject>Antitubercular Agents - therapeutic use</subject><subject>Bacteriological Techniques</subject><subject>China</subject><subject>DNA Gyrase - genetics</subject><subject>DNA Mutational Analysis - methods</subject><subject>Drug Resistance, Multiple, Bacterial - genetics</subject><subject>Genotype</subject><subject>Humans</subject><subject>Kanamycin</subject><subject>Kanamycin - therapeutic use</subject><subject>Kanamycin Resistance - genetics</subject><subject>Microbial Sensitivity Tests</subject><subject>Multidrug-resistant tuberculosis</subject><subject>Multiplex allele specific PCR</subject><subject>Multiplex Polymerase Chain Reaction</subject><subject>Mutation</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Mycobacterium tuberculosis - genetics</subject><subject>Mycobacterium tuberculosis - pathogenicity</subject><subject>Ofloxacin</subject><subject>Ofloxacin - therapeutic use</subject><subject>Predictive Value of Tests</subject><subject>Ribosomal Proteins - genetics</subject><subject>Tuberculosis, Multidrug-Resistant - diagnosis</subject><subject>Tuberculosis, Multidrug-Resistant - drug therapy</subject><subject>Tuberculosis, Multidrug-Resistant - microbiology</subject><issn>1472-9792</issn><issn>1873-281X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtr3DAUhUVp6KRp_0AXRctuPNHDsmzIJgzpAwYSQgLdCVm6nmqQH5HkkJA_H5mZdBm4IKF7zkHnQ-gbJWtKaHW-X6e5hTUjVK5JHko-oFNaS16wmv79mO-lZEUjG7ZCn2Pck2wiNfmEVqwhgkghTtHL5TR5Bxb3s09u8vCEtffgAccJjOucwTebW5xGbCGBSTiCGQdbeDcAtmHe4QDRxaQHA1j347A7JC2r4m2V8PLRYGY_5gfsBrz55wb9BZ102kf4ejzP0P3Pq7vN72J7_evP5nJbGC6qVHBKGWNWyEbm2l0reVMZTXjX6lraXKVqrRCEcsm0qUxVM83LypSCgW6b0vAz9OOQO4XxYYaYVO-iAe_1AOMcFW1ESSrRlDxL2UFqwhhjgE5NwfU6PCtK1AJd7dXSRS3QFclDSTZ9P-bPbQ_2v-WNchZcHASQWz46CCoaB5mYdSEzVXZ07-W_Aje_lKs</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Liang, Ya-ping</creator><creator>Chen, Yan</creator><creator>Xiao, Tong-yang</creator><creator>Xia, Qiang</creator><creator>Liu, Hai-can</creator><creator>Zhao, Xiu-qin</creator><creator>Zeng, Chun-yan</creator><creator>Zhao, Li-li</creator><creator>Wan, Kang-lin</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201712</creationdate><title>Applied multiplex allele specific PCR to detect second-line drug resistance among multidrug-resistant tuberculosis in China</title><author>Liang, Ya-ping ; Chen, Yan ; Xiao, Tong-yang ; Xia, Qiang ; Liu, Hai-can ; Zhao, Xiu-qin ; Zeng, Chun-yan ; Zhao, Li-li ; Wan, Kang-lin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-311222d5797101fb7396ca03fba87d2906bd5501372ac6c682a346c452eab94c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antitubercular Agents - therapeutic use</topic><topic>Bacteriological Techniques</topic><topic>China</topic><topic>DNA Gyrase - genetics</topic><topic>DNA Mutational Analysis - methods</topic><topic>Drug Resistance, Multiple, Bacterial - genetics</topic><topic>Genotype</topic><topic>Humans</topic><topic>Kanamycin</topic><topic>Kanamycin - therapeutic use</topic><topic>Kanamycin Resistance - genetics</topic><topic>Microbial Sensitivity Tests</topic><topic>Multidrug-resistant tuberculosis</topic><topic>Multiplex allele specific PCR</topic><topic>Multiplex Polymerase Chain Reaction</topic><topic>Mutation</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Mycobacterium tuberculosis - genetics</topic><topic>Mycobacterium tuberculosis - pathogenicity</topic><topic>Ofloxacin</topic><topic>Ofloxacin - therapeutic use</topic><topic>Predictive Value of Tests</topic><topic>Ribosomal Proteins - genetics</topic><topic>Tuberculosis, Multidrug-Resistant - diagnosis</topic><topic>Tuberculosis, Multidrug-Resistant - drug therapy</topic><topic>Tuberculosis, Multidrug-Resistant - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liang, Ya-ping</creatorcontrib><creatorcontrib>Chen, Yan</creatorcontrib><creatorcontrib>Xiao, Tong-yang</creatorcontrib><creatorcontrib>Xia, Qiang</creatorcontrib><creatorcontrib>Liu, Hai-can</creatorcontrib><creatorcontrib>Zhao, Xiu-qin</creatorcontrib><creatorcontrib>Zeng, Chun-yan</creatorcontrib><creatorcontrib>Zhao, Li-li</creatorcontrib><creatorcontrib>Wan, Kang-lin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Tuberculosis (Edinburgh, Scotland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liang, Ya-ping</au><au>Chen, Yan</au><au>Xiao, Tong-yang</au><au>Xia, Qiang</au><au>Liu, Hai-can</au><au>Zhao, Xiu-qin</au><au>Zeng, Chun-yan</au><au>Zhao, Li-li</au><au>Wan, Kang-lin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Applied multiplex allele specific PCR to detect second-line drug resistance among multidrug-resistant tuberculosis in China</atitle><jtitle>Tuberculosis (Edinburgh, Scotland)</jtitle><addtitle>Tuberculosis (Edinb)</addtitle><date>2017-12</date><risdate>2017</risdate><volume>107</volume><spage>1</spage><epage>4</epage><pages>1-4</pages><issn>1472-9792</issn><eissn>1873-281X</eissn><abstract>Rapid detection of resistance to the second-line drugs is essential for early initiation of appropriate anti-tubercular treatment regimen among multi-drug tuberculosis (MDR-TB). In this study, we applied a multiplex allele-specific PCR (MAS-PCR) to identify the mutations on codons 90 and 94 of gyrA and nucleotide 1401 of rrs for detecting ofloxacin (OFX) and kanamycin (KAN) resistance in 139 MDR-TB isolates from China. Using the traditional phenotypic method as the reference, MAS-PCR detected resistance to OFX and KAN with sensitivities of 67.3% and 76.5%, respectively, and specificities of 100.0%. Therefore, MAS-PCR assays can be used for rapid detection of second-line drug resistance among MDR-TB in China, enabling early administration of appropriate treatment regimens to the affected MDR-TB patients.</abstract><cop>Scotland</cop><pub>Elsevier Ltd</pub><pmid>29050755</pmid><doi>10.1016/j.tube.2017.07.010</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1472-9792 |
| ispartof | Tuberculosis (Edinburgh, Scotland), 2017-12, Vol.107, p.1-4 |
| issn | 1472-9792 1873-281X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1954065943 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antitubercular Agents - therapeutic use Bacteriological Techniques China DNA Gyrase - genetics DNA Mutational Analysis - methods Drug Resistance, Multiple, Bacterial - genetics Genotype Humans Kanamycin Kanamycin - therapeutic use Kanamycin Resistance - genetics Microbial Sensitivity Tests Multidrug-resistant tuberculosis Multiplex allele specific PCR Multiplex Polymerase Chain Reaction Mutation Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - genetics Mycobacterium tuberculosis - pathogenicity Ofloxacin Ofloxacin - therapeutic use Predictive Value of Tests Ribosomal Proteins - genetics Tuberculosis, Multidrug-Resistant - diagnosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - microbiology |
| title | Applied multiplex allele specific PCR to detect second-line drug resistance among multidrug-resistant tuberculosis in China |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T09%3A48%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Applied%20multiplex%20allele%20specific%20PCR%20to%20detect%20second-line%20drug%20resistance%20among%20multidrug-resistant%20tuberculosis%20in%20China&rft.jtitle=Tuberculosis%20(Edinburgh,%20Scotland)&rft.au=Liang,%20Ya-ping&rft.date=2017-12&rft.volume=107&rft.spage=1&rft.epage=4&rft.pages=1-4&rft.issn=1472-9792&rft.eissn=1873-281X&rft_id=info:doi/10.1016/j.tube.2017.07.010&rft_dat=%3Cproquest_cross%3E1954065943%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1954065943&rft_id=info:pmid/29050755&rft_els_id=S1472979216303006&rfr_iscdi=true |